MIRM in the 13F filings
Mirum Pharmaceuticals Inc · CUSIP 604749101
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 10 listed it in both
- Shares listed
- 14,787,998
- combined, among listed positions
- Reported value
- $1.2bn
- combined, at the quarter end
Among the 92 comparable managers: 14 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +158,908.
Managers listing MIRM in Q4 2025
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 6,065,308 shares now+1,067,722
- Wellington Management Group LLPexisting position · 1,237,830 shares now+447,141
- T. Rowe Price Associates Incexisting position · 1,420,375 shares now+137,087
- Marshall Wace LLPexisting position · 102,703 shares now+62,871
- Two Sigma Investments LPexisting position · 388,542 shares now+45,416
Reductions
- Point72 Asset Management LPexisting position · 190,638 shares now-600,037
- Arrowstreet Capital LPexisting position · 372,511 shares now-239,807
- Citadel Advisors LLCexisting position · 840,220 shares now-200,324
- Voloridge Investment Management LLCexisting position · 297,950 shares now-91,624
- Renaissance Technologies LLCexisting position · 439,085 shares now-74,363
New positions and exits
New (3)
Exited (4)
- Jane Street Group LLCwas $19m
- Brevan Howard Capital Management LPwas $762k
- Schonfeld Strategic Advisors LLCwas $536k
- Quantbot Technologies LPwas $33k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $1.7m | n.a. | n.a. |
| Q3 2022 | 1 | $7.5m | n.a. | n.a. |
| Q4 2022 | 1 | $7.0m | n.a. | n.a. |
| Q1 2023 | 2 | $26m | n.a. | n.a. |
| Q2 2023 | 2 | $24m | n.a. | n.a. |
| Q3 2023 | 3 | $87m | n.a. | n.a. |
| Q4 2023 | 2 | $68m | 1 | 1 |
| Q1 2024 | 2 | $75m | 1 | 1 |
| Q2 2024 | 3 | $179m | 2 | 1 |
| Q3 2024 | 3 | $192m | 2 | 1 |
| Q4 2024 | 3 | $211m | 3 | 0 |
| Q1 2025 | 3 | $251m | 3 | 0 |
| Q2 2025 | 4 | $304m | 4 | 0 |
| Q3 2025 | 10 | $609m | 6 | 2 |
| Q4 2025 | 8 | $613m | 14 | 15 |
| Q1 2026 | 11 | $1.1bn | 20 | 11 |
| Q2 2026 | 10 | $1.6bn | 11 | 20 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MIRM and LLY →MIRM and JNJ →MIRM and VRTX →Choose a stock to compare with MIRM →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MIRM, latest filings →Back to the 13F Explorer →